Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289273 · ClinicalTrials.gov registry record
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,010
- Enrollment target
NCT03289273 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,010 participants.
The verdict
NCT03289273 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,010 participants
- Enrollment target
Study Summary
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2022-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289273
The ClinicalTrials.gov registry entry for NCT03289273 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,010 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT03289273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289273 about?
NCT03289273 is a clinical study titled "Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)". Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
What is the current status of trial NCT03289273?
This trial is currently completed. The enrollment target is 1,010 participants. The study started on 2017-09-13. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT03289273?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT03289273?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.